Atanu Roy

Atanu Roy, PhD, has a diverse background in the pharmaceutical and biotechnology industry. Atanu currently holds the position of Vice President, Chemistry at SeqLL Inc., where they oversee the chemistry department. Prior to this role, they served as a Principal Scientist at SeqLL Inc. from 2016 to 2022.

Before joining SeqLL Inc., Dr. Roy worked at Moderna Therapeutics in Cambridge, MA, USA, where they held the position of Senior Scientist. During their time there, they played a crucial role in establishing the Medicinal/Organic Chemistry lab and led the screening platform for Moderna's chemical library. Atanu was involved in the synthesis and screening of over 1,000 modified mRNA compounds with distinct chemistries. Dr. Roy's key therapeutic areas of focus at Moderna included oncology, cardiovascular, rare diseases, and infectious diseases.

Prior to their role at Moderna, Dr. Roy was a Senior Scientist at Helicos BioSciences in Cambridge, MA, USA. There, they contributed to the design and synthesis of DNA polymerase inhibitors and specialized in hit-to-lead and lead optimization. Atanu also played a role in developing genetic analysis technologies, including the design and synthesis of innovative inhibitors and dinucleotides.

Dr. Roy began their career at Auburn University in AL, USA, where they held the position of Senior Research Fellow & Post-Doctoral Research Associate. Atanu served as a lab and group leader and mentored graduate students in their research in synthetic organic and medicinal chemistry. Atanu also managed various responsibilities related to sample preparation, data compilation, and collaboration with research professionals involved in oncology and antiviral screening programs.

Overall, Dr. Atanu Roy's work experience demonstrates their expertise in medicinal and organic chemistry, assay development, and project management within the pharmaceutical and biotechnology industry.

Atanu Roy, PhD, obtained their doctoral degree in Synthetic Organic & Medicinal Chemistry from the Indian Institute of Chemical Biology. Following their PhD, they pursued a post-doctoral position in Synthetic Organic and Medicinal Chemistry at Auburn University.